HELEN HESLOP to Burkitt Lymphoma
This is a "connection" page, showing publications HELEN HESLOP has written about Burkitt Lymphoma.
Connection Strength
1.295
-
Sensitizing Burkitt lymphoma to EBV-CTLs. Blood. 2020 05 21; 135(21):1822-1823.
Score: 0.577
-
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma. Clin Lymphoma Myeloma. 2006 Jan; 6(4):342-7.
Score: 0.213
-
Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 02; 30(2):217-227.
Score: 0.183
-
Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist. 2003; 8(1):83-98.
Score: 0.173
-
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
Score: 0.128
-
Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Res. 2002 Dec 15; 62(24):7195-9.
Score: 0.011
-
Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res. 2002; 84:175-201.
Score: 0.010